US-based multi-state operator Cresco Labs (CSE:CL,OTCQX:CRLBF) is reducing its offer for Origin House (CSE:OH,OTCQX:ORHOF) as the deal moves forward on new terms.

The Illinois-based cannabis producer confirmed on Wednesday (November 13) that its all-stock deal — once referred to by the firm as the “largest-ever public company acquisition” in the US cannabis space — is proceeding with a non-brokered financing on the part of Origin House.

Origin House will have to complete the financing of over 9.7 million of its own common shares at a cost of C$4.08 per share, for a total amount of C$39.6 million. Cresco Labs said the funding will help reinforce the balance sheet for the company once the merger is complete.

As part of the change, Cresco will also be lowering its payable subordinate voting shares. Now, the company will have to provide 0.7031 Cresco shares for each common Origin House share and 70.31 Cresco shares for each Class A compressed Origin House share. Figures in the original deal stood at 0.8428 and 84.28 Cresco shares, respectively.

The deal is still subject to customary closing conditions and is now set to close by mid-January 2020.

Proceeds from the financing will be held in escrow until the agreement is complete. Origin House will use common shares to pay certain unnamed persons, including service providers, what they’re owed.

The news follows the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period for Cresco’s deal back in October, helping inch the deal towards completion after being scrutinized by the US Department of Justice.

The transaction was first announced in April this year and was valued at C$1.1 billion. Since then, the markets have been unfavorable for the cannabis industry, resulting in sharp drops in value across the board for players in the space.

Marc Lustig, CEO of Origin House, said in a statement that he continues to be optimistic about the deal despite the shift in market conditions.

“The equity market environment has changed meaningfully since we first announced this proposed transaction. While this has presented challenges, it will also present opportunities for companies with quality assets and brands to quickly gain market share and build long-term shareholder value.”

Cresco CEO Charlie Bachtell told investors the addition of Origin House’s assets will be essential in improving Cresco’s market share in California and across the US.

Bachtell told investors this past summer that while the federal review was an “intrusive” process into the plans of the company, it gave the firm the chance to speak directly with federal authorities about the marijuana market as a legitimate business industry.

“The fact that a federal agency is reviewing (a mergers and acquisitions) transaction in this industry must be seen as validation,” Bachtell previously said.

Shares of Cresco Labs had dropped 7.5 percent on Wednesday to C$7.82 as of 10:58 a.m. EST from a closing price of C$8.45 on Tuesday (November 12).

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less